Zacks Research Upgrades DENTSPLY SIRONA (NASDAQ:XRAY) to Hold

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other research firms also recently commented on XRAY. Barclays started coverage on shares of DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective on the stock. JPMorgan Chase & Co. reduced their price target on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Wells Fargo & Company lifted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Finally, Barrington Research increased their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday. Three analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, DENTSPLY SIRONA currently has an average rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Stock Down 7.1%

Shares of DENTSPLY SIRONA stock opened at $13.30 on Monday. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18. The company has a market capitalization of $2.66 billion, a PE ratio of -4.43, a P/E/G ratio of 1.68 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The business has a 50-day moving average of $12.52 and a 200-day moving average of $12.47.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same period in the prior year, the company posted $0.26 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Insider Activity

In related news, Director Gregory T. Lucier acquired 22,445 shares of DENTSPLY SIRONA stock in a transaction that occurred on Tuesday, March 3rd. The stock was acquired at an average price of $14.03 per share, for a total transaction of $314,903.35. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $701,500. This trade represents a 81.46% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.52% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds have recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. bought a new position in shares of DENTSPLY SIRONA during the fourth quarter worth about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the 1st quarter worth about $26,000. Parkside Financial Bank & Trust grew its position in DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares during the last quarter. Huntington National Bank increased its stake in shares of DENTSPLY SIRONA by 292.9% in the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 2,077 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 2,122 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
• Neutral Sentiment: Mizuho raised its price target to $16 but kept a “neutral” rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
• Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
• Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
• Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.